Colorectal cancer: Dichotomous or continuum model? Perhaps, a combination of both

Gut

Volumn 62, Issue 10, 2013, Pages 1519-1520

  Papagiorgis, Petros ^a  

^a ATHENS MEDICAL CENTER   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BETA CATENIN; CYCLOOXYGENASE 2; PROTEIN P53; RAS PROTEIN;

CANCER MODEL; CANCER RISK; CHROMOSOMAL INSTABILITY; COLONOSCOPY; COLORECTAL CANCER; CPG ISLAND; FAT INTAKE; FOOD INTAKE; GENE MUTATION; HUMAN; LETTER; MICROSATELLITE INSTABILITY; OBESITY; PHYSICAL INACTIVITY; PRIORITY JOURNAL; SMOKING;

CARCINOGENESIS; COLORECTAL CANCER; MOLECULAR MECHANISMS;

COLORECTAL NEOPLASMS; HUMANS;

EID: 84884285512     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-305209     Document Type: Letter

References (6)

1. Yamauchi M, Lochhead P, Morikawa T, et al. Colorectal cancer. A tale of two sides or a continuum? Gut 2012;61:794-7.
2. Iacopetta B. Are there two sites to colorectal cancer? Int J Cancer 2002;101:403-8.
3. Greystoke A, Mullamitha SA. How many diseases are colorectal cancer? Gastroenterol Res Pract 2012. doi:10.1155/2012/564741
4. Wray CM, Ziogas A, Hinojosa M, et al. Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum 2009;52:1359-66.
5. Li F, Lai M. Colorectal cancer, one entity or three. J Zhejiang Univ Sci B 2009;10:219-29.
6. Russo A, Bazan V, Iacopetta D, et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005;23:7518-28. (Pubitemid 46291815)